These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 7081978)

  • 1. Vancomycin pharmacokinetics in normal and morbidly obese subjects.
    Blouin RA; Bauer LA; Miller DD; Record KE; Griffen WO
    Antimicrob Agents Chemother; 1982 Apr; 21(4):575-80. PubMed ID: 7081978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vancomycin dosing in morbidly obese patients.
    Bauer LA; Black DJ; Lill JS
    Eur J Clin Pharmacol; 1998 Oct; 54(8):621-5. PubMed ID: 9860149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals.
    Smit C; Wasmann RE; Goulooze SC; Wiezer MJ; van Dongen EPA; Mouton JW; Brüggemann RJM; Knibbe CAJ
    Br J Clin Pharmacol; 2020 Feb; 86(2):303-317. PubMed ID: 31661553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theophylline disposition in obesity.
    Gal P; Jusko WJ; Yurchak AM; Franklin BA
    Clin Pharmacol Ther; 1978 Apr; 23(4):438-44. PubMed ID: 630791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
    Pai MP; Norenberg JP; Anderson T; Goade DW; Rodvold KA; Telepak RA; Mercier RC
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2741-7. PubMed ID: 17548489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.
    Bauer LA; Edwards WA; Dellinger EP; Simonowitz DA
    Eur J Clin Pharmacol; 1983; 24(5):643-7. PubMed ID: 6873144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.
    van Kralingen S; Diepstraten J; Peeters MY; Deneer VH; van Ramshorst B; Wiezer RJ; van Dongen EP; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2011 Nov; 50(11):739-50. PubMed ID: 21973271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propofol clearance in morbidly obese children and adolescents: influence of age and body size.
    Diepstraten J; Chidambaran V; Sadhasivam S; Esslinger HR; Cox SL; Inge TH; Knibbe CA; Vinks AA
    Clin Pharmacokinet; 2012 Aug; 51(8):543-51. PubMed ID: 22690673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size.
    Diepstraten J; Chidambaran V; Sadhasivam S; Esslinger HR; Cox SL; Inge TH; Knibbe CA; Vinks AA
    Clin Pharmacokinet; 2012 Aug; 51(8):543-551. PubMed ID: 28258392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients.
    Smit C; Wasmann RE; Goulooze SC; Hazebroek EJ; Van Dongen EPA; Burgers DMT; Mouton JW; Brüggemann RJM; Knibbe CAJ
    Clin Pharmacokinet; 2019 Oct; 58(10):1333-1343. PubMed ID: 31016671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procainamide disposition in obesity.
    Christoff PB; Conti DR; Naylor C; Jusko WJ
    Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.
    Bunnell KL; Pai MP; Sikka M; Bleasdale SC; Wenzler E; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29311094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of vancomycin in a morbidly obese patient.
    Penzak SR; Gubbins PO; Rodvold KA; Hickerson SL
    Ther Drug Monit; 1998 Jun; 20(3):261-5. PubMed ID: 9631922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.
    Vance-Bryan K; Guay DR; Gilliland SS; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 1993 Mar; 37(3):436-40. PubMed ID: 8460912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remifentanil pharmacokinetics in obese versus lean patients.
    Egan TD; Huizinga B; Gupta SK; Jaarsma RL; Sperry RJ; Yee JB; Muir KT
    Anesthesiology; 1998 Sep; 89(3):562-73. PubMed ID: 9743391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery.
    Xu B; Zhou D; Ren L; Shulman S; Zhang X; Xiong M
    J Anesth; 2017 Dec; 31(6):813-820. PubMed ID: 28828532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.
    Healy DP; Polk RE; Garson ML; Rock DT; Comstock TJ
    Antimicrob Agents Chemother; 1987 Mar; 31(3):393-7. PubMed ID: 3579256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenobarbital pharmacokinetics in obesity. A case report.
    Wilkes L; Danziger LH; Rodvold KA
    Clin Pharmacokinet; 1992 Jun; 22(6):481-4. PubMed ID: 1587059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.
    Rotschafer JC; Crossley K; Zaske DE; Mead K; Sawchuk RJ; Solem LD
    Antimicrob Agents Chemother; 1982 Sep; 22(3):391-4. PubMed ID: 7137982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.